ABSTRACT
Background: Benefi cial effect in reducing microalbuminuria of diabetic nephropathy with angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) is proven. This study has directly compared the renoprotective effects of ARB and ACE inhibitors in persons with type-2 diabetes. Methods: In this prospective, double-blind, controlled trial, 100 patients with type 2 diabetes mellitus were chosen and randomly assigned to either receive ACE inhibitor (ramipril 5 mg, 50 patients) or ARB (losartan 50 mg, 50 patients). The endpoint was a reduction in 24 hrs urine microalbuminuria after a period of 3 months treatment. Results: At the end of 3 months treatment, the mean reduction of 24 hrs urine microalbuminuria in the ramipril group was 25 mg as compared to 38 mg in the losartan group; (t value=1.11, p=0.27). There was no statistical difference in the mean reduction when compared between the two groups. Signifi cant reduction of blood pressure especially systolic blood pressure was noted in the losartan group as compared to those who received ramipril. Conclusion: Losartan was not inferior to ramipril in providing renoprotection in subjects with type 2 diabetes and early nephropathy. Losartan showed a signifi cant reduction in systolic blood pressure, though not much reduction was seen with ramipril. Despite this, both drugs have shown a reduction in microalbuminuria, which supports the fact that reduction in microalbuminuria is independent of the antihypertensive action of ramipril or losartan.
ABSTRACT
Background: The metabolic syndrome consists of a constellation of metabolic abnormalities including central obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, hyperglycemia and hypertension. Aims & Objective: To study serum uric acid level in metabolic syndrome. Materials and Methods: The present study was conducted on fifty patients with metabolic syndrome as per IDF criteria and waist circumference, blood pressure, serum uric acid were estimated. Results: There is significant correlation found between serum uric acid levels and hypertension and also between serum uric acid levels and waist circumference of metabolic syndrome patients. Conclusion: Patients with higher serum uric acid levels has significant correlation with components of metabolic syndrome is one of the risk factor in development of atherosclerosis and cardiovascular disease.